Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0KQ8A
|
||||
| Former ID |
DNC010167
|
||||
| Drug Name |
Tyr-Pro-Trp-D-Val-Bn
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C37H44N6O5
|
||||
| Canonical SMILES |
CC(C)C(C(=O)NCC1=CC=CC=C1)NC(=O)C(CC2=CNC3=CC=CC=C32)NC<br />(=O)C4CCCN4C(=O)C(CC5=CC=C(C=C5)O)N
|
||||
| InChI |
1S/C37H44N6O5/c1-23(2)33(36(47)40-21-25-9-4-3-5-10-25)42-34(45)31(20-26-22-39-30-12-7-6-11-28(26)30)41-35(46)32-13-8-18-43(32)37(48)29(38)19-24-14-16-27(44)17-15-24/h3-7,9-12,14-17,22-23,29,31-33,39,44H,8,13,18-21,38H2,1-2H3,(H,40,47)(H,41,46)(H,42,45)/t29-,31-,32-,33+/m0/s1
|
||||
| InChIKey |
FBLJJMPPZKDLDJ-DMBLRCPMSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Mu-type opioid receptor | Target Info | Inhibitor | [1] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| Estrogen signaling pathway | |||||
| Morphine addiction | |||||
| NetPath Pathway | TCR Signaling Pathway | ||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Enkephalin release | |||||
| Pathway Interaction Database | IL4-mediated signaling events | ||||
| Reactome | Peptide ligand-binding receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | TCR Signaling Pathway | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| Peptide GPCRs | |||||
| Opioid Signalling | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Bioorg Med Chem Lett. 2009 Sep 15;19(18):5387-91. Epub 2009 Jul 30.Molecular modeling studies to predict the possible binding modes of endomorphin analogs in mu opioid receptor. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.